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Abstract
Chronic pain hypersensitivity depends upon N-methyl-D-aspartate receptors (NMDARs).
However, clinical use of NMDAR blockers is limited by side effects from suppressing
physiological functions of these receptors. Here we report a means to suppress pain
hypersensitivity without blocking NMDARs but rather by inhibiting the binding of a key enhancer
of NMDAR function, the protein tyrosine kinase Src. We show that a peptide consisting of amino
acids 40-49 of Src fused to the protein transduction domain of the HIV Tat protein (Src40-49Tat)
prevented pain behaviors induced by intraplantar formalin and reversed pain hypersensitivity
produced by intraplantar injection of complete Freund’s adjuvant or by peripheral nerve injury.
Src40-49Tat had no effect on basal sensory thresholds, acute nociceptive responses, or
cardiovascular, respiratory, locomotor or cognitive functions. Thus, by targeting Src-mediated
enhancement of NMDARs, inflammatory and neuropathic pain are suppressed without deleterious
consequences of directly blocking NMDARs, an approach that may be of broad relevance to
managing chronic pain.
Chronic pain is categorized as inflammatory or neuropathic, each involving neuroplastic
changes leading to hypersensitivity in peripheral and central nociceptive systems1,2.
Multiple mechanisms including increased primary afferent excitability3, enhanced
transmission in the dorsal horn1, changes in gene expression4, aberrant neuron-glia
interactions5,6 and neuronal apoptosis7 are implicated in hypersensitivity in chronic pain
models. Abundant pre-clinical evidence indicates that N-methyl-D-aspartate receptor
(NMDARs)8 are critically involved in pain hypersensitivity9–11. However, pharmacological
blockade of these receptors in humans is deleterious because the activity of NMDARs is
essential for many important physiological functions including breathing and
locomotion9,12,13. A crucial signaling event for NMDAR-dependent neuroplasticity,
including pain hypersensitivity1,14, is upregulation of NMDAR currents by mechanisms
including relieving Mg2+ blockade and receptor phosphorylation15,16. Thus, preferentially
inhibiting mechanisms which upregulate NMDARs without affecting basal channel activity
represents a strategy that may suppress pain hypersensitivity without impairing key
physiological functions.
NMDARs are multiprotein complexes comprised of a core tetrameric assembly -- two NR1
subunits and two NR2A-2D subunits – which form the ion channel conductance
pathway8,17. Within the NMDAR complex, the non-receptor tyrosine kinase Src is a critical
regulatory hub through which multiple intracellular signaling cascades converge to increase
NMDAR activity16. Src is anchored within the NMDAR complex through an adaptor
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protein which we have identified as NADH dehydrogenase subunit 2 (ND2)18. Blocking the
interaction between the Src unique domain and ND2 releases Src from the NMDAR
complex, separating the enzyme and substrate, thereby inhibiting Src-mediated upregulation
of NMDAR activity18. Hence, disrupting the Src-ND2 interaction is a strategy to treat pain
that not only avoids the undesirable effects of blocking NMDAR function but avoids
directly inhibiting the catalytic activity of Src, a widely expressed kinase19. In the present
study, we tested the hypothesis that uncoupling Src from the NMDAR complex may
suppress pain hypersensitivity (Fig. 1a).
RESULTS
Constructing a Src-NMDAR uncoupling peptide for use in vivo
In order to develop a practical reagent to disrupt anchoring of Src in the NMDAR complex
in vivo, we synthesized a series of overlapping 10-amino acid peptides covering Src40-58,
the region in the unique domain we had previously identified in vitro as crucial for the Src-
ND2 interaction18. We found that a peptide consisting of amino acids 40-49 of Src,
Src40-49, but not Src45-54 or Src49-58, bound to ND2.1, the interacting region of ND2
(Fig. 1b). Moreover, Src40-49 disrupted the interaction between the Src unique domain and
ND2.1 in vitro (Supplementary Fig. 1a).
Intracellular administration of Src40-49 reduced the NMDAR component of the miniature
excitatory post-synaptic currents20 in cultured dorsal horn neurons (Fig. 1c), neurons in
which NMDARs are tonically upregulated by Src14,21,22. By contrast, administering a
peptide with identical amino acid composition but with a scrambled sequence (sSrc40-49)
had no effect on synaptic NMDAR currents. The AMPAR component of the mEPSCs was
unaffected by either Src40-49 or sSrc40-49. Thus, in vitro, Src40-49 disrupts the Src-ND2
interaction and reduces the upregulation of synaptic NMDARs.
Because Src40-49 is predicted to be membrane impermeant, this peptide itself is unsuitable
for use in vivo. Therefore, we synthesized Src40-49, as well as sSrc40-49, fused to the
protein transduction domain of the HIV-1 Tat protein23, generating Src40-49Tat and
sSrc40-49Tat, respectively. Src40-49Tat, but not sSrc40-49Tat, bound to the ND2.1
fragment of ND2 in vitro (Fig 1d). As we had previously observed with Src40-5818,
Src40-49Tat did not bind to the ND2.2 or ND2.3 fragments of ND2 (Supplementary Fig.
1b). Therefore, adding the Tat protein transduction domain did not abrogate the binding to
ND2, and Src40-49Tat retains specificity for the ND2.1 region.
We found next that Src40-49Tat, but not sSrc40-49Tat, disrupted the direct interaction
between the Src unique domain and ND2.1 (Fig 1e). Furthermore, by immunoprecipitating
either NMDAR complexes or Src from rat brain crude synaptosomes we found that
incubating in vitro with Src40-49Tat, but not sSrc40-49Tat, suppressed their association
(Fig. 1f,g). Src40-49Tat also suppressed the association of Src with ND2 (Fig. 1g) but had
no effect on the interaction between ND2 and NMDARs (Supplementary Fig. 1c), indicating
that Src40-49Tat caused a loss of Src from the NMDAR complex by inhibiting the binding
of this kinase to ND2. In contrast, Src40-49Tat did not affect the association of Fyn or
PSD-95 with NMDARs (Supplementary Fig. 1d,e) demonstrating that this peptide did not
generally disrupt interactions between proteins in the NMDAR complex. Moreover,
Src40-49Tat had no effect on Src catalytic activity at the concentration which disrupted the
Src-ND2 interaction or at 10 times this concentration (Supplementary Fig. 1g), indicating
that Src40-49Tat is not a Src kinase inhibitor per se.
Administering Src40-49Tat intravenously had no effect on the amount of Src, ND2 or
NMDARs in rat brain synaptosomes. However, co-immunoprecipitation of ND2 and of
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NMDARs with Src was reduced in synaptosomes from animals in which Src40-49Tat had
been administered in vivo as compared with that in synaptosomes from control rats (Fig.
1h). From the findings collectively, we concluded that Src40-49Tat is suitable for in vivo
studies on the role of the Src-ND2 interaction in pain hypersensitivity.
Src40-49Tat prevents formalin-induced pain behaviors
We first tested Src40-49Tat in an inflammatory pain model in which dilute formalin was
injected into the rat hindpaw, causing a stereotypic two-phase pattern of behavioral
responses24,25 : phase 1 is independent of NMDARs whereas phase 2 is NMDAR-
dependent4,26. We found that pretreating with Src40-49Tat (i.v. 45 min before formalin), but
not sSrc40-49Tat, saline vehicle or Tat-protein transduction domain alone, significantly
reduced formalin-induced phase 2 flinching (Fig. 2a,b) and biting or licking behaviors
(Supplementary Fig. 2a). In contrast, responses in phase 1 were indistinguishable among all
groups tested (Fig. 2c). Moreover, intravenous administration of Src40-49Tat had no effect
on formalin-induced paw edema27 (Fig. 2d).
We then tested Src40-49Tat at 100 times the lowest maximally effective dose, on basal
sensory thresholds and locomotor function in naïve rats, and found no alteration in thermal
or mechanical thresholds, or rota-rod performance (Supplementary Fig. 2b–d). . Src40-49Tat
i.v. also had no effect on heart rate, respiratory rate or oxygen saturation (Supplementary
Table 1). Therefore, administering Src40-49Tat differentially suppresses the second, but not
the first, phase of formalin-induced behaviors without causing observable changes in
peripheral inflammation, basal sensory thresholds, locomotor performance or cardio-
respiratory functions.
In order to determine whether Src40-49Tat may act within the spinal cord to suppress
formalin-induced behaviors, we administered the peptide intrathecally at the lumbar level.
We found that administering Src40-49Tat i.t. 30 min prior to formalin had no effect on
behaviors in phase 1 whereas the peptide significantly reduced phase 2 behaviors (Fig. 2e,f,
Supplementary Fig. 2e). As the dose of Src40-49Tat i.t. was 20 times less than the minimal
dose that produced an effect by i.v. injection, we concluded that when Src40-49Tat was
given intrathecally, the suppression of phase 2 behaviors was mediated within the spinal
cord.
We examined the effect of Src40-49Tat on the interactions between Src, ND2 and NMDARs
in animals treated with formalin. Intravenously administering Src40-49Tat, but not
sSrc40-49Tat, disrupted the association between Src and ND2, and Src and NMDARs in the
spinal cord (Fig. 3a), without changing the association between ND2 and NMDARs
(Supplementary Fig. 1f). Furthermore, we found that injection of formalin produced an
approximately 2.5-fold increase in the level of tyrosine phosphorylation of NR2B subunit of
the NMDAR in the lumbar dorsal horn ipsilateral to the formalin injection (Fig. 3b). This
increase was prevented by Src40-49Tat (i.t.) but not by sSrc40-49Tat (Fig. 3c). Thus, pre-
treating with Src40-49Tat suppressed formalin-induced behaviors, disrupted the Src-ND2
interaction in the spinal cord, and reduced the formalin-induced increase in tyrosine
phosphorylation of NR2B within the spinal cord.
Src40-49Tat reverses CFA-induced pain behaviors
We next investigated the effect of Src40-49Tat on established inflammatory pain using
thermal and mechanical hypersensitivity evoked by intraplantar injection of Complete
Freund’s Adjuvant28 (CFA; Fig. 4). Intravenous administration of Src40-49Tat, but not
vehicle or sSrc40-49Tat, caused an increase in the CFA-sensitized paw-withdrawal latency
(Fig. 4a,b,c) indicating that the peptide inhibited the established thermal hypersensitivity.
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The magnitude of reversal of hypersensitivity increased with dose in the range of 0–10pmol
g−1 and persisted up to 120 min at the maximum dose of Src40-49Tat. Src40-49Tat, but not
sSrc40-49Tat, also reversed the increase in tyrosine phosphorylation of NR2B in the
ipsilateral spinal dorsal horn that occurred one day after CFA (Fig. 4 inset). Thermal
hypersensitivity induced by CFA was also suppressed by intravenous administration of 4-
amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2), a broad-spectrum
inhibitor of Src-family kinases16, which had a maximum effect similar to that of
Src40-49Tat (Supplementary Fig. 3a,b). The effects of PP2 and Src40-49Tat were not
additive, however (Supplementary Fig. 3b), implying that inhibiting Src-kinases broadly
produced no further reversal of the CFA-induced thermal hypersensitivity than did
Src40-49Tat alone.
Another consequence of intraplantar CFA is mechanical hypersensitivity. We found that
mechanical hypersensitivity was suppressed for up to 2 h by Src40-49Tat i.v. (Fig. 4d) but
unaffected by sSrc40-49Tat. Thus, Src40-49Tat reversed the established thermal and
mechanical pain hypersensitivity produced by the inflammatory stimulus CFA.
Src40-49Tat does not affect learning
We investigated the possible effect of Src40-49Tat on two forms of NMDAR-dependent
learning and memory: contextual fear conditioning29 and conditioned taste aversion30,31. In
both tasks, we administered Src40-49Tat prior to training and then examined memory 3 days
later. For contextual fear conditioning, Src40-49Tat, given intravenously at doses equal or
up to 100 times those eliciting maximal suppression of formalin-induced behaviors,
produced no change in freezing behavior as compared with saline controls (Supplementary
Fig. 4a,b). For conditioned taste aversion, Src 40-49Tat was microinfused bilaterally into the
insular cortex 30 min prior to training. Src40-49Tat had no effect on taste preference during
the choice test (supplementary Fig. 4d). As a positive control for the injection site,
subsequent lidocaine microinfusion into the same group of mice was able to attenuate taste
preference (Supplementary Fig. 4e). Thus, in two behavioral paradigms Src40-49Tat did not
affect learning and memory.
Suppression of inflammatory pain behaviors requires Src
We investigated Src-dependency of effects of Src40-49Tat on inflammatory pain behaviors
using Src null mutant mice32. Src−/− mice were not different from wild-type littermate
controls in acute thermal or mechanical nociceptive responses, in locomotor function as
measured by the accelerated rota-rod test (Supplementary Fig. 5a–d), in Morris water maze
testing or in contextual fear conditioning (Supplementary Fig. 5 e,f). Formalin-induced
behaviors in phase 1 were unaltered in Src−/− mice (Fig. 5a). However, formalin-induced
behaviors in phase 2 were significantly reduced in Src null mutant mice as compared with
wild-type littermate controls (Fig. 5a,b). There was no difference between wild-type and
Src−/− mice in the basal level of tyrosine phosphorylation of NR2B in dorsal spinal cord
(Supplementary Fig. 6a). However, after formalin administration, the increase in tyrosine
phosphorylation of NR2B in the spinal dorsal horn in the wild-type did not occur in Src−/−
mice (Fig. 5c). Thus, as anticipated from our findings with administering Src40-49Tat,
formalin-induced behaviors in the second phase, but not in the first phase, and formalin-
induced NR2B tyrosine phosphorylation in the dorsal horn are dependent upon Src.
We reasoned that if the effects of Src40-49Tat are mediated by uncoupling of Src from the
NMDAR complex, then these effects will be lost in the absence of Src. To test this, we
compared the effect of Src40-49Tat on formalin-induced behaviors in Src−/− versus wild-
type littermates. As with our findings using rats, administering Src40-49Tat i.v. 45 min
before formalin in wild-type mice had no effect on phase 1 behaviors (Fig. 5d) but
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significantly reduced formalin-induced phase 2 behaviors (Fig. 5d,e). By contrast, in the Src
null mutant mice, intravenously administered Src40-49Tat had no effect on formalin-
induced phase 2 behaviors (Fig. 5f; Supplementary Figure 6b,c). Because phase 2 behaviors
were suppressed in Src−/− mice but were not further inhibited by Src40-49Tat, we infer that
the effect of the peptide was occluded in the Src null mutant mice. Formalin-induced
behaviors in Src−/− mice were suppressed by morphine (Supplementary Fig. 7a), indicating
that these mice are not generally resistant to analgesics. Thus, our results indicate that the
suppression of inflammatory pain behaviors by Src40-49Tat is Src-dependent.
Src40-49Tat reverses nerve-induced pain behaviors
We next tested Src40-49Tat on neuropathic pain behaviors using a model of peripheral
nerve injury (PNI) in rats characterized by a reduction of mechanical paw withdrawal
threshold and cold-induced sensitization33,34. The effect of Src40-49Tat on mechanical
withdrawal threshold was assessed 8–15 d after PNI5,35. We found that Src40-49Tat, but not
sSrc40-49Tat or saline vehicle, caused a significant increase in paw withdrawal threshold
ipsilateral to the nerve injury when administered either intrathecally (Fig. 6a) or
intravenously (Fig. 6b). The increase in paw withdrawal threshold developed within the first
hour, and with intrathecal administration the effect persisted for the 5-h testing period. With
intravenous administration, the increase in paw withdrawal threshold peaked approximately
2 h after injecting Src40-49Tat. With either intrathecal or intravenous administration, paw
withdrawal threshold had returned to the pre-injection level by 24 h after the peptide was
injected (data not illustrated).
Cold-induced sensitization was assessed by applying a drop of acetone to the plantar surface
of the paw, which evokes flinching, and licking or biting behaviors36. Administering
Src40-49Tat significantly reduced acetone-induced behaviors but sSrc40-49Tat had no
effect (Fig. 6c; Supplementary Fig. 7b).
We found that the level of tyrosine phosphorylation of NR2B in the ipsilateral spinal cord
was significantly increased by PNI with no effect on total NRB (Fig. 6d). Intrathecal
administration of Src40-49Tat reduced the level of NR2B tyrosine phosphorylation in PNI
animals to a level not different from that in sham controls (Fig. 6d). Collectively, our results
indicate that Src40-49Tat reverses PNI-induced mechanical and cold sensitization and that,
acting at the level of the spinal cord, Src40-49Tat normalizes PNI-induced NR2B tyrosine
phosphorylation.
We tested Src-dependency of PNI-induced mechanical hypersensitivity by comparing Src−/−
mice and wild-type littermate controls. In wild-type mice, PNI caused a marked reduction in
paw withdrawal threshold of the ipsilateral paw beginning one day following PNI and
persisting for more than 3 weeks (Fig. 6e). In Src−/− mice the reduction in paw withdrawal
threshold was significantly less than that in the wild-type mice throughout the 22-d period
during which the mice were examined (Fig. 6e). Correspondingly, the PNI-induced increase
in tyrosine phosphorylation of NR2B in the ipsilateral dorsal spinal cord was reduced in
Src−/− mice compared with that in wild-type littermates (Fig. 6e inset). Src40-49Tat i.v.
significantly increased paw withdrawal threshold in wild-type mice 14 d after PNI, (Fig. 6f),
to a level not different from that in the Src−/− mice without peptide administration (Fig. 6f).
However, Src40-49Tat. had no effect on paw withdrawal threshold in the Src null mutant
mice. Likewise, when administered 3 d after PNI, Src40-49Tat significantly increased paw
withdrawal threshold in wild-type mice but not in Src−/− mice (Supplementary Fig. 7c).
Thus, we concluded that the suppression of mechanical hypersensitivity by Src40-49 was
occluded in Src−/− mice, and as such, that this effect is Src-dependent.
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DISCUSSION
Our findings show that the Src40-49Tat peptide, but not the scrambled Src40-49Tat peptide,
suppresses pain hypersensitivity induced by inflammation and peripheral nerve injury. By
contrast, Src40-49Tat caused no alteration in acute thermal, mechanical or chemical
nociception. Because there appeared to be no confounding sedative, motor depressant, or
cognitive effects of the peptide (see Supplementary Discussion), we conclude that
Src40-49Tat suppresses pain hypersensitivity, and that behaviors in models of chronic pain
are suppressed preferentially with respect to those in acute nociception. Moreover, in Src
null mutant mice both the formalin- and PNI-induced pain hypersensitivity were reduced
and the effects of Src40-49Tat were occluded in these animals. Together these findings
demonstrate that a common link between inflammatory and neuropathic pain behaviors is
dependency upon Src. The most parsimonious interpretation of our findings is that the
suppression of pain hypersensitivity behaviors by Src40-49Tat may be mediated by
disruption of the Src-ND2 interaction and subsequent inhibition of Src-induced
enhancement of NMDAR function.
We designed Src40-49Tat to inhibit the interaction of Src with its anchoring protein, ND2,
in the NMDAR complex. The binding of Src40-49Tat to ND2 in and of itself cannot account
for the behavioral effects of the peptide, because the ND2 level within the NMDAR
complex is not changed in Src null mice37, and yet the pain hypersensitivity was not affected
by Src40-49Tat in these animals. By similar reasoning, potential binding of Src40-49Tat to
molecules other than ND2 may remain in Src−/− mice and thus, such off-target interactions,
if they exist, are not responsible for the suppression of pain hypersensitivity by the peptide.
Rather, the suppression of pain hypersensitivity by Src40-49Tat may require an intact
interaction between Src and ND2, which is inhibited by the peptide. It is conceivable that
Src40-49Tat might inhibit an interaction of Src with a partner other than ND2, that has the
same Src40-49 binding motif as does ND2. However, the Src-binding region of ND2, which
is highly conserved in mouse, rat and humans18, contains no known conserved domains or
motifs, and shows minimal primary sequence homology to other proteins.
Within the NMDAR complex, Src enhances NMDAR function by increasing channel open
time and open probability upon binding of the co-agonists glutamate and glycine, leading to
increased synaptic NMDARs currents14. Src is opposed by the phosphotyrosine phosphatase
STEP21, and the balance of the activity between these two enzymes provides dynamic gain
control of NMDAR function16. Our findings indicate that peripheral inflammation causes a
rapid onset and sustained Src-dependent increase in tyrosine phosphorylation, which may
enhance the function of NMDARs in the spinal cord. The reversal of the decreased paw
withdrawal threshold by Src40-49Tat several weeks after PNI likewise implies that there is
an ongoing increase in Src activity relative to STEP, which is required to sustain pain
hypersensitivity after PNI. Many candidate intracellular signaling pathways might cause the
relative increase in Src activity within the NMDAR complex16,38,39 that produces pain
hypersensitivity, and it is conceivable these pathways may be common, or distinct, for
inflammatory versus neuropathic pain.
The kinase most closely related to Src is Fyn, and PNI-induced behaviors are suppressed in
Fyn null mutant mice40, indicating that Fyn may also be important for these behaviors. It is
known that Fyn does not interact with ND218 and here we found that Src40-49Tat does not
affect the association of Fyn with NMDARs. Moreover, the effects of Src40-49Tat were
prevented in Src−/− mice, which do express Fyn. Collectively, these findings indicate that
Src40-49Tat does not act directly through Fyn. In the case of PNI, it is possible that Fyn
may be downstream of Src and hence, that Fyn might be indirectly affected by Src40-49Tat.
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Inhibitors of Src family kinases (SFKs) targeting the catalytic domain have been reported to
reduce CFA-induced mechanical hyperalgesia41 and PNI-induced behaviors42, and we show
here that PP2 reduces CFA-induced thermal hyperalgesia. SFK inhibitors do not distinguish
well between members of the Src family43. By contrast, Src40-49 corresponds to a sequence
in the unique domain, which has no primary sequence homology to that in any other SFK.
Catalytic domain inhibitors block the kinase regardless of substrate. However, Src40-49Tat
does not inhibit kinase catalytic activity but rather separates the kinase from its substrate.
Thus, two strategic advantages of Src40-49Tat are that it suppresses the action of Src
differentially from other SFKs, and that it does this only for substrates where Src targeting
to the protein depends upon the Src-ND2 interaction, as does that of the NMDAR18.
Distinguishing between inflammatory versus neuropathic pain may be difficult clinically.
Thus, an efficacious therapy that simultaneously suppresses both inflammatory and
neuropathic pain, and at the same time has a wide therapeutic window, would have the
advantage of being effective and safe, and could simplify pain management strategies. Our
present discoveries open up the possibility that such a therapeutic approach may be achieved
by targeting the Src-mediated enhancement of NMDAR function. NMDARs are implicated
in many disease processes in the CNS, including neurodegenerative disorders, epilepsy and
stroke. From our present findings it is possible that potentiated NMDAR function, by Src or
other pathways, rather than basal receptor function, is crucial for these disorders as well.
Thus, our findings reveal a strategy relevant to the treatment of chronic pain, and potentially
other NMDAR-dependent CNS pathologies.
METHODS
Animals
All animals were used in accordance with the guidelines of the Canadian Council on Animal
Care. Male Sprague–Dawley rats used for behavioral studies were purchased from Charles
River, Montreal QC. The c-Src null mutation was introduced by homologous recombination
into embryonic stem cells as described previously32. The mice used in contextual fear and
CTA experiments were the offspring (F1) from a cross between C57Bl/6Tac (B6; Taconic
Farms) and 129Sv/Tac (129; Taconic Farms). Mice were bred in the animal colony at the
Hospital for Sick Children according to Research Institute guidelines. ANOVA or Student’s
t test were used to determine significant differences between sample groups for behavioral
testing. p < 0.05 was considered significant in all cases.
Models for inflammatory or neuropathic pain
To produce inflammatory pain, formalin (2.5%, 50 μl for rats, 1.5%, 20μl for mice) or
Complete Freund’s adjuvant (CFA) (0.05ml of Mycobacterium tuberculosis) was
subcutaneously injected into the plantar hindpaw. For the formalin test, two animals in
adjacent chambers were observed at one time, for flinching behaviors or biting and licking
time 44 with observations occurring in alternate 2 min period out of a 4 min bin. Data were
presented either as time course, or cumulative number of flinches and the total amount of
time with biting and licking behaviors during phase 1 (0–8 min) or phase 2 (9–60 min). For
the CFA model, thermal paw withdrawal latency (PWL)28, 45 and mechanical paw
withdrawal threshold (PWT) were measured. Data were presented either as a raw data or
normalized for each animal as the percentage Maximal Possible Effect (MPE) in terms of
the change in the PWL ipsilateral to CFA. These values were calculated as follows:
Percentage MPE = (TimeX PWL−Tim 0 PWL)/(baseline − Time 0 PWL ). Time 0 is the
PWL 24 h following CFA, before drug ministration. TimeX is the time point following
Src40-49Tat, PP2 or their respective controls injection. To produce peripheral nerve injury
(PNI), a polyethylene cuff (2 mm in length) was surgically implanted around the sciatic
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nerve of rats or mice under isoflurane anesthesia5,35 Mechanical paw withdrawal
threshold5, 35 and cold sensitization36 were measured as previously described. See
Supplementary Methods online for details of thermal paw withdrawal latency testing,
mechanical paw withdrawal threshold testing, and cold sensitization testing.
Peptides
Src40-49 (KPASADGHRG), scrambled Src40-49 (GAAKRPSDGH), Tat protein
transduction domain (YGRKKRRQRRR), Src40-49Tat
(KPASADGHRGYGRKKRRQRRR) and scrambled Src40-49Tat
(GAAKRPSDGHYGRKKRRQRRR) were synthesized by the Advanced Protein
Technology Center, Toronto, Canada.
Co-Immunoprecipitation, Immunoprecipitation and Immunoblotting
For co-immunoprecipitation NMDAR and its associated proteins, crude synaptosomal
fraction from forebrain or spinal cord was prepared as described previously21. For in vitro
competition experiments, Src40-49Tat or Scrambled Src40-49Tat,(10μM), was incubated
with the lysate 30 min before adding antibody for immunoprecipitation.
For immunoprecipitation to examine the relative tyrosine phosphorylation of NR2B, we
rapidly removed the dorsal lumbar spinal cord ipsilateral to formalin or CFA or PNI. Each
sample contained proteins from one animal, and was homogenized, immunoprecipitated and
analyzed individually. Spinal cord was homogenizated as described41 in ice cold RIPA
buffer. centrifuged and the protein concentration determined. Samples were then incubated
with NR2B antiserum (Santa Cruz Biotechnology) overnight. Immune complexes were
isolated by protein G-Sepharose beads, resolved by SDS-PAGE and transferred to
nitrocellulose membranes. Membranes were first probed with an antibody against
phosphotyrosine, then stripped and reprobed with an antibody against NR2B. For
densitometric quantification, immunoblots were digitized and quantified using ImageJ
software. The relative phosphotyrosine NR2B band density (relative p-NR2B density) levels
were obtained by normalizing the anti-phosphotyrosine immunoblot against the
corresponding NR2B subunit immunoblot from the same sample. A linear detection range
was established for each antibody used, and only values falling in this linear range were
incorporated into the final quantitative analysis. ANOVA and an unpaired two-tailed t test
were used to determine significant differences between sample groups. p < 0.05 was
considered significant in all cases.
Electrophysiological recordings
Whole-cell recordings were made from cultured dorsal horn neurons as described20.
Src(40-49) or sSrc(40-49) were added to the intracellular solution for a final concentration
of 0.015 mg ml−1. Whole-cell currents were recorded with an AxoPatch 200B amplifier
(Axon Instruments), digitized (20 KHz) and analyzed offline. Detection and analysis of
mEPSCs was done off-line (MiniAnalysis Program, Synaptosoft). Average mEPSCs
observed in the first two min after breaking in whole-cell configuration were used as control
and compared to averages obtained after 8–14 min in whole-cell. The AMPA component
was measured at the maximum amplitude during the first 5 ms in each event and the NMDA
component as the integrated charge between 5–150 ms after the peak value15. Mean
mEPSCs contained at least 30 traces. See Supplementary Methods online for more details.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Src40-49Tat suppresses the Src-NMDAR interaction in vitro and in vivo. (a) Cartoon
illustrating the main hypothesis. Domain structure of Src shows Src-homology (SH)
domains 1,2,3 and the unique domain (UD). (b) Dot blot of ND2.1-GST fusion protein
probed with biotinylated Src unique domain peptide with overlapping sequence of 40-58,
followed by streptavidin-HRP (SA-HRP). (c) Effect of Src 40-49 on mEPSCs. Left panel,
average mEPSCs in the first two min after breaking in to whole-cell configuration was
superimposed with averages obtained after 8–14 min. Right panel: the ratio of measurements
during the first two min and from 8–14 min (Src40-49 n = 11; sSrc40-49 n =5). (d) Dot blot
of ND2.1-GST fusion protein probed with biotinylated Src40-49Tat or scrambled
Src40-49Tat followed by SA-HRP. (e) In vitro binding assay of assays with ND2.1-GST and
Src unique domain, with no peptide, Src40-49Tat or sSrc40-49Tat (30μM). Src unique
domain bound to ND2.1-GST was probed with antibody against Src, stripped and reprobed
with antibody against GST. (f–h) Immunoblots of coimmunoprecipitates obtained with
antibody against NR2B (anti-NR2B, f) or antibody against Src (anti-Src, g–h) from brain
crude synaptosomes (f–g) in vitro incubated with Src40-49Tat or sSrc40-49Tat (10μM) or
(h) from animals with or without Src40-49Tat (100pmol g−1) intravenous injection (45 min
before sample collection). Blots were probed with respective antibodies as labeled.
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Fig. 2.
Src40-49Tat suppresses formalin-induced behaviors in rats with intravenous or intrathecal
administration. (a) Time course of flinches induced by formalin (2.5%), with Src40-49Tat
(1pmol g−1, i.v.) or sSrc40-49Tat (1pmol g−1, i.v.) 45 min before formalin ( n=10). (b–c)
The effect of Src40-49Tat (0.001–10pmol g−1, i.v. n=10) on formalin-induced phase 2 (9–
60min, b) or phase1 (0–8 min, c) flinches. Scrambled Src40-49Tat (1pmol g−1, n=10), Tat-
protein transduction domain alone (Tat-PTD) (1pmol g−1 n=10) or saline vehicle (n=28)
were used as controls (*p<0.05 vs. saline controls). (d) The effect of Src40-49Tat,
Scrambled Src40-49Tat or Tat-PTD (i.v., 1pmol g−1 n=8) on formalin-induced paw edema.
(e–f) The effect of intrathecal Src40-49Tat (5×10−4 pmol g−1, 30 min pretreatment) on
formalin-induced flinches. (e) time course, (f) total number of flinches (n=8, **p<0.01 vs.
saline treated controls). (mean±s.e.m. for all groups)
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Fig. 3.
Src40-49Tat disrupts Src association with ND2 and with NMDAR, and prevents formalin-
induced increase in tyrosine phosphorylation of the NR2B in spinal cord dorsal horn. (a)
Representative immunoblots of lysate (left) or co-immunoprecipitates obtained with
antibody against Src from spinal cord crude synaptosomes in naïve animals, or in animals
with Src40-49Tat and sSrc40-49Tat (10pmol g−1, i.v., 45 before formalin). Samples were
collected 30 min following formalin. The blots were probed with antibody against NR1, and
stripped and reprobed with antibodies against ND2 and against Src. (b-c) Representative
immunoblots (left panel) of immunoprecipitates obtained with antibody against NR2B from
ipsilateral dorsal lumbar spinal cord following formalin injection, probed with antibodies
against phosphotyrosine (anti-pTyr ) and against NR2B. Right panel shows a histogram of
relative tyrosine phosphorylation of NR2B (Relative p-NR2B density; see Methods),
normalized to naïve. (b) Samples were collected in naïve rats or at 10, 30, and 60 min
following formalin injection, (c) Rats were treated intrathecally with Src40-49Tat or
sSrc40-49Tat (5×10−4 pmol g−1), and samples were collected 60 min following formalin
injection. (mean±s.e.m.; n=6–10, each analyzed individually *p<0.05 vs. naïve control).
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Fig. 4.
Src40-49Tat reverses CFA-induced thermal and mechanical hypersensitivity. (a) CFA
injection reduces ipsilateral paw withdrawal latency (PWL) to radiant heat 24 h following
CFA. (b) The effect of Src40-49Tat (10 pmol g−1, i.v.) on CFA-induced thermal
hypersensitivity in terms of percentage Maximal Possible Effect (MPE; see Methods) of
PWL. Inset: immunoblot and histogram showing tyrosine phosphorylation of NR2B 24 h
after CFA and effects of Src40-49Tat or sSrc40-49Tat on normalized p-NR2B band
intensity. (c) Histogram illustrating effects Src40-49Tat (0.1, 1 or 10 pmol g−1, i.v.) or of
sSrc40-49Tat (10 pmol g−1, i.v.) or saline (0) on CFA-induced changes in PWL, expressed
as percentage MPE of PWL. (d) The effect of Src40-49Tat and sSrc40-49Tat (10pmol g−1
i.v.) on CFA-induced reduction of paw withdrawal threshold (PWT) to Von-Frey stimuli in
the ipsilateral paw, 6 h following CFA. (*p<0.05, **p<0.01 vs. control; mean±s.e.m.; n=5–
9).
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Fig. 5.
The effect of Src40-49Tat on formalin-induced behavior is occluded in Src null mutant
mice. Time course (a) and total phase 2 flinches (b) induced by 1.5% formalin in Src−/−
mice and littermate wild-type mice (mean±s.e.m, n=5 mice, ***p<0.005 vs. wild-type
littermate control, Src+/+). (c) Representative immunoblots (left panel) of
immunoprecipitates obtained with NR2B antibody from spinal cord of Src−/− or Src+/+ mice,
60 min after formalin injection. The immunoprecipitates were probed with antibodies
against phosphotyrosine and against NR2B. Right panel: a histogram of relative p-NR2B
band density of spinal dorsal horn from Src+/+ and Src−/− mice treated with formalin,
normalized to Src+/+ mice (mean±s.e.m.; n=3–7 mice,. *p<0.05 vs. wild-type littermates).
(d–f) The effect of Src40-49Tat (0.5pmol g−1 i.v.) on formalin-induced flinches in (d–
e)wild-type control mice and (f) Src null mutant mice (mean±s.e.m., n=6–8 mice,
***p<0.005 vs. non-treated control mice).
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Fig. 6.
The effect of Src40-49Tat on peripheral nerve injury-induced tactile and cold
hypersensitivity. (a–b) The effect of Src40-49Tat on PNI-induced decrease of paw
withdrawal thresholds (PWT) in rats with (a) intrathecal Src40-49Tat, sSrc40-49Tat (5×10−4
pmol g−1) or (b) intravenous Src40-49Tat (10pmol g−1) administration. BI, before injury,
PNI, peripheral nerve injury (n=10–16, *p<0.05, vs. saline control). (c) The effect of
Src40-49Tat on acetone-induced flinches in rats following PNI. Acetone was applied before
or 30 and 60 min after Src40-49Tat or sSrc40-49Tat (10 pmol g−1 i.v.) (*p<0.05 vs. pre-
peptide control. n=4). (d) The effect of intrathecal Src40-49Tat (5×10−4 pmol g−1) on PNI-
induced increase in relative p-Tyr-NR2B density in rat spinal cord. Left panel: a histogram
of the relative p-NR2B density normalized to sham, and right panel: representative
immunoblots of immunoprecipitates obtained with antibody against NR2B and probed with
antibodies against phosphotyrosine and against NR2B. (sample were collected 5 h following
Src40-49Tat; n=5, *p<0.05 vs. sham; #p<0.05 vs. PNI ). (e) PWT in Src−/− and Src+/+ mice,
day 1–22 after PNI. Inset: representative immunoblots of immunoprecipitates obtained with
antibody against NR2B from spinal cord of Src−/− and Src+/+ mice, 22 days following PNI,
probed with antibodies against phosphotyrosine and against NR2B (f) The effect of
Src40-49Tat (5 pmol g−1, i.v.) on PWT of Src−/− and Src+/+ mice, day 14 after PNI (e–f:
n=8–11, *p<0.05, **p<0.01, ***p<0.001 vs. controls). (mean±s.e.m for all groups).
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